This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A second look: Discussing the phase 3 CREDIT clinical trials of Sintbilo (Tafolecimab Injection) in patients with primary hypercholesterolemia and mixed dyslipidemia.

Ticker(s): 1801.XHKG

Who's the expert?

Institution: Penn Medicine 

  • Echo Lab Director, Vascular Lab Director, and Clinical Assistant Professor of Medicine at Penn Medicine Valley Forge
  • Areas of expertise include Aortic Disorders, Atherosclerosis, Paroxysmal Supraventricular Tachycardia, Hypertension
  • Manages approximately 500 patients with heart failure, and prescribes Farxiga for about 50 patients

Interview Goal
To discuss the current standard of care and the potential of Sintbilo (Tafolecimab Injection), an anti-PCSK9 monoclonal antibody being developed by Innovent Biologics for the treatment of patients with primary hypercholesterolemia and mixed dyslipidemia.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.